Explosion in pharmaceutical manufacturer Arenol's Sommerville, N.J. facility endangers supply of Adderall and Dextrostat, Shire's products for the treatment of attention deficit/hyperactivity disorder. Shire will either restart manufacturing at Arenol or transfer agreements to an alternative facility. Shire predicts sufficient supply for the next 3-4 months, but does not expect to re-establish a source of active ingredient before the exhaustion of currently available stocks. The supply halt will likely have an adverse effect on Shire's financial condition, as Adderall and Dextrostat represented 63% of Shire's revenue in the six months ended June 30
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth